Phenominer Database Results (12 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Experiment Notes Record ID Study ID
PVG.1AV1 post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 15 14.6 d 0.4 1.55 in vivo visual assessment 0.0 69778 1162
PVG.1AV1 percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98.0 days-200.0 days 8 100.0 % ex vivo visual assessment 0.0 peripheral nervous system integrity trait 84516 1178
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 15 33.0 % in vivo visual assessment 0.0 69710 1162
PVG.1AV1 percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98.0 days-200.0 days 4 25.0 % ex vivo visual assessment 0.0 peripheral nervous system integrity trait 84530 1178
PVG.1AV1 serum orosomucoid 1 level Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120.0 days-180.0 days 15 340.0 mg/l radial immunodiffusion assay 0.0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69754 1162
PVG.1AV1 serum orosomucoid 1 level pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120.0 days-180.0 days 18 340.0 mg/l radial immunodiffusion assay 0.0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69764 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 10 0.0 % in vivo visual assessment 0.0 69704 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 15 0.0 % in vivo visual assessment 0.0 69707 1162
PVG.1AV1 serum orosomucoid 1 level squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120.0 days-180.0 days 10 150.0 mg/l radial immunodiffusion assay 0.0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69751 1162
PVG.1AV1 serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120.0 days-180.0 days 15 250.0 mg/l radial immunodiffusion assay 0.0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69757 1162
PVG.1AV1 post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 18 38.0 d 1.2 5.09 in vivo visual assessment 0.0 69785 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120.0 days-200.0 days 18 33.0 % in vivo visual assessment 0.0 69717 1162